Updating results

Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: TBC

Technology appraisal guidance In development

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Tinnitus: assessment and management

In development [GID-NG10077] Expected publication date: 11 March 2020

NICE guideline In development

Diabetes in pregnancy: management from preconception to the postnatal period

In development [GID-NG10158] Expected publication date: TBC

NICE guideline In development

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

In development [GID-NG10161] Expected publication date: TBC

NICE guideline In development

Type 1 diabetes in adults: diagnosis and management (update)

In development [GID-NG10159] Expected publication date: TBC

NICE guideline In development

Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

NICE guideline In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Technology appraisal guidance In development

ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Technology appraisal guidance In development

Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Technology appraisal guidance In development

Preterm labour and birth (update)

In development [GID-NG10078] Expected publication date: 02 August 2019

NICE guideline In development

Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Technology appraisal guidance In development

NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Technology appraisal guidance In development

Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Technology appraisal guidance In development

Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: 11 August 2020

Technology appraisal guidance In development

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: 16 December 2020

Technology appraisal guidance Proposed

Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 01 September 2021

NICE guideline In development

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: 15 December 2021

Technology appraisal guidance In development

Neonatal parenteral nutrition

In development [GID-NG10037] Expected publication date: 26 February 2020

NICE guideline In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Dupilumab for treating severe asthma [ID1213]

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance In development

Diabetes update

In development [GID-NG10152] Expected publication date: TBC

NICE guideline In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Technology appraisal guidance In development

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 03 February 2021

NICE guideline In development

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed